Clinical trials: Insulin Pump
Diabetes Mellitus, Type 1
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluated a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study was conducted in participants with type 1 diabetes mellitus to investigate how the human body…
- Trial name
- NCT02703324
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Treated With Insulin
Lifestyle Intervention in Type 2 Diabetes
The purpose of the study is to determine whether a personalized lifestyle intervention focused on diet and physical activity reinforcement is effective in avoiding weight gain in the first months following initiation of…
- Trial name
- WeightPump (NCT02791295)
- Testing
- Diet and physical activity program
- Where
- 6 sites in France
- Volunteers
- 54 people
- Sponsor
- Icadom
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections.
- Trial name
- STAR2 (NCT00530023)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
- Trial name
- NCT00874809
- Testing
- CGMS with an insulin pump using rapid acting insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diabetes Care Center
Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes.
- Trial name
- NCT00097071
- Testing
- insulin lispro, insulin aspart
- Where
- 52 sites in United States
- Volunteers
- 299 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes (T1D)
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes.
- Trial name
- Hybrid CATT1 (NCT07616206)
- Testing
- Cadisegliatin 800 mg QD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- vTv Therapeutics
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Study of the Impact of PROximity Support for Patients With Type 1 DIABetes Treated With an Insulin Pump or Closed Loop.
Amidst medical innovations, many Type 1 diabetes patients using advanced therapy show improved control but still suffer from diabetes-related distress.
- Trial name
- PRO-DIAB-1 (NCT06050642)
- Testing
- enhanced care model provided by Timkl, a home support provider
- Where
- France
- Volunteers
- 340 people
- Sponsor
- timkl
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study.
- Trial name
- NCT01134107
- Testing
- Insulin Lispro 6 Day (6D), Insulin Aspart 6 Day (6D)
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
- Trial name
- NCT01110746
- Testing
- Viaject 7, LISPRO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biodel
Diabetes Mellitus
MEDTRUM A7+ TouchCare Insulin Patch Pump (MedInPS)
Demonstration study of the interest of the MEDTRUM A7+ TouchCare insulin patch pump versus INSULET Omnipod® patch pump
- Trial name
- MedInPS (NCT04223973)
- Testing
- Medtrum A7+ insulin Pump, Lab A1C
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Medtrum France
Diabetes Type 1
Glycemic Control and Quality of Life Evolution for Patients With T1D Using the myLoop Powered by CamAPS FX System in Combination With FreeStyle Libre 3 / 3 Plus Sensors in France
The goal of this observational study is to learn how glucose control changes over one year in people with type 1 diabetes who use the myLoop with CamAPS FX and Freestyle Libre 3 or FreeStyle Libre 3 Plus during usual care in…
- Trial name
- NCT07835685
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 220 people
- Sponsor
- mylife Diabetes Care AG
Diabetes Mellitus, Insulin-Dependent
Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies
The study is a prospective, multi-center, open label, randomized; two-arms cross over study. This is the test protocol for the InsuPatch device, whose purpose is to improve insulin delivery into the blood when the insulin is…
- Trial name
- NCT01216618
- Testing
- InsuPatch
- Where
- 3 sites in United States, Israel
- Volunteers
- 55 people
- Sponsor
- Insuline Medical Ltd.
Type 1 Diabetes Mellitus
Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting
The purpose of this study is to evaluate the performance of an insulin pump controlling algorithm while the subject is under close medical supervision in the Clinical Research Center (CRC) setting.
- Trial name
- NCT01401751
- Testing
- Hypoglycemia-Hyperglycemia Minimizer System
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Animas Corporation
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
PUMP STUDY MDI Lantus/Lispro vs Continuous Insulin+Lispro
Whether a once-daily basal injection of insulin glargine with mealtime injections of insulin lispro achieves equivalent glycaemic control (HbA1c) to administration of insulin lispro by continuous subcutaneous insulin infusion in…
- Trial name
- NCT00540709
- Testing
- Insulin Glargine
- Volunteers
- 58 people
- Sponsor
- Sanofi